

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

(11) Publication number:

0 220 805  
A2

(12)

# EUROPEAN PATENT APPLICATION

(21) Application number: 86306216.2

(51) Int. Cl.<sup>4</sup> A61K 9/24

(22) Date of filing: 12.08.86

The title of the invention has been amended  
(Guidelines for Examination in the EPO, A-III,  
7.3).

(30) Priority: 28.08.85 GB 8521350

(43) Date of publication of application:  
06.05.87 Bulletin 87/19(84) Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE(71) Applicant: Euroceltique SA  
122 Boulevard De La Petrusse  
Luxembourg(LU)

(72) Inventor: Elger, Gordon Anthony  
99 Greenfields Earith  
Huntingdon Cambs.(GB)  
Inventor: Leslie, Stewart Thomas  
4 Babraham Road  
Cambridge, CB2 2RA(GB)  
Inventor: Malkowska, Sandra Therese  
Anoinette  
14 Abrahams Close  
Landbeach Cambridge(GB)  
Inventor: Miller, Ronald Brown  
Bruderholzallee, 191  
Basel 4059(CH)  
Inventor: Neale, Phillip John  
28, London Road  
Harston Cambridge, CB2 5QH(GB)

(74) Representative: James, Stephen Richard,  
Napp Pharmaceutical Group Cambridge  
Science Park Milton Road  
Cambridge CB4 4GW(GB)

(54) Multiphase tablet and process for the preparation thereof.

EP 0 220 805 A2

(57) A pharmaceutical composition in the form of a multiphase (especially a bilayered, optionally coated) tablet. The tablet has a narcotic analgesic phase containing a therapeutically effective quantity of a narcotic analgesic or an analgesically effective salt thereof (e.g. codeine phosphate) and a non-steroidal anti-inflammatory phase containing a therapeutically effective quantity of a non-steroidal anti-inflammatory carboxylic acid or an anti-inflammatory salt or ester thereof (e.g. ibuprofen). The narcotic analgesic phase is free from a non-steroidal anti-inflammatory carboxylic acid or salt or ester thereof, stearic acid and a stearate salt, and the non-steroidal anti-inflammatory phase is free from a narcotic analgesic or salt thereof, stearic acid and a stearate salt. Further, both the narcotic analgesic phase and the non-steroidal anti-inflammatory phase contain a self-lubricating, compression aid, especially a self-lubricating, direct compression aid, such as microcrystalline cellulose.

## PHARMACEUTICAL COMPOSITION

This invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for the relief of mild to severe pain and for the treatment of inflammation in musculo-skeletal disorders.

Narcotic analgesics, such as codeine and dihydrocodeine, have been used in the relief of pain, especially mild to severe pain. Severe pain, in particular, requires the use of large and increasing doses of a narcotic analgesic.

A major disadvantage of narcotic analgesics is that patients may develop a dependence and tolerance to their action. Further adverse reactions, such as respiratory and circulatory depression, are observed when large doses of narcotic analgesics are used.

Non-steroidal anti-inflammatory drugs, such as ibuprofen, have been used in rheumatic and degenerative diseases of the joints, for reducing platelet adhesiveness and for dental pain.

European Patent Application No. 68838A (Upjohn) describes the synergistic effect obtained for the management of moderate to severe pain when a combination of narcotic analgesic and ibuprofen is administered.

In the Examples of EP 68838A, tablets containing morphine, ibuprofen and magnesium stearate as lubricant, are disclosed. The applicant also states, at page 9, lines 22 to 26, that tablets containing ibuprofen and codeine may be prepared simply by replacing the morphine in the exemplified tablets with codeine.

The present inventors have found that tablets containing a narcotic analgesic, such as codeine, a non-steroidal anti-inflammatory carboxylic acid, such as ibuprofen, and magnesium stearate, as described in EP 68838A, exhibit serious incompatibility, poor crushing strength and long disintegration times.

It is therefore a primary object of the present invention to provide a tablet containing both a narcotic analgesic and a non-steroidal anti-inflammatory carboxylic acid which overcomes, to a substantial degree, the above problems.

Other objects and advantages of the present invention will become apparent from the following detailed description thereof.

According to the present invention there is provided a pharmaceutical composition in the form of a multiphase tablet comprising at least one narcotic analgesic phase containing a therapeutically effective quantity of a narcotic analgesic or an analgesically effective salt thereof and at least one non-steroidal anti-inflammatory phase containing a therapeutically effective quantity of a non-steroidal anti-inflammatory carboxylic acid or an anti-inflammatory salt or ester thereof wherein the at least one narcotic analgesic phase is free from a non-steroidal anti-inflammatory carboxylic acid or salt or ester thereof, stearic acid and a stearate salt, and the at least one non-steroidal anti-inflammatory phase is free from a narcotic analgesic or salt thereof, stearic acid and a stearate salt, and further wherein, both the at least one narcotic analgesic phase and the at least one non-steroidal anti-inflammatory phase contain at least one self-lubricating, compression aid.

Preferably the self-lubricating compression aid is a self-lubricating, direct compression aid.

Preferably the composition is in the form of a layered tablet, especially a bilayer tablet. Optionally the layered tablet may be film coated.

The narcotic analgesic may be naturally occurring, semi-synthetic or synthetic. Examples include pentazocine (HCl salt), pethidine (HCl salt) and phenazocine (HBr salt). Preferably, however, the narcotic analgesic is a morphinan-6-ol or a morphinan-6-one derivative, especially morphine (sulphate), ethylmorphine (HCl salt), hydromorphone (HCl salt), hydrocodone (tartrate), dihydrocodeine (tartrate) and, which is particularly preferred, codeine (phosphate).

Analgesically effective salts of the narcotic analgesics of the present invention must be pharmaceutically acceptable.

The non-steroidal anti-inflammatory carboxylic acid will generally be an aromatic or heterocyclic carboxylic acid. Examples include aspirin, fenbufen, flufenamic acid, indomethacin, meclofenamic acid - (sodium salt), sulindac and tolmetin (sodium salt). Preferably, however, the non-steroidal anti-inflammatory carboxylic acid is a benzeneacetic acid, such as alclofenac, diclofenac (sodium salt) and fenclofenac, a 2-naphthylpropionic acid, such as naproxen (sodium salt), or, which is particularly preferred, a 2-phenylpropionic acid, such as fenoprofen (sodium or calcium salt), flurbiprofen, indoprofen, ketoprofen and, especially, ibuprofen.

Anti-inflammatory effective salts or esters of the non-steroidal anti-inflammatory carboxylic acids of the present invention must be pharmaceutically acceptable, e.g. alkali metal salt and C<sub>1</sub>-C<sub>4</sub> alkyl esters.

Therapeutically effective quantities of the present narcotic analgesics or salts thereof and non-steroidal anti-inflammatory carboxylic acids or salts or esters thereof will be sufficient, in combination, either to relieve mild to severe pain or to treat inflammatory conditions.

Preferred therapeutically effective quantities of the preferred narcotic analgesics and the preferred non-steroidal anti-inflammatory carboxylic acids of this invention are listed in the Table,

**TABLE**

Therapeutically effective quantity

<u>Narcotic Analgesic</u>	Preferred	Particularly Preferred
	<u>Single Dose</u>	<u>Single Dose</u>
Codeine	5-60mg	7.5-30mg
Dihydrocodeine	10-60mg	20-40mg
Ethylmorphine	5-60mg	
Hydrocodone	5-20mg	
Hydromorphone	1-5mg	
Morphine	2-120mg	5-100mg.
Pentazocine	10-100mg	
Pethidine	20-150mg	
Phenazocine	2.5-20mg	
<u>Non Steroidal</u>		
<u>Anti-inflammatory</u>		
<u>Carboxylic Acid</u>		
Aspirin	200-1000mg	300-900mg

0 220 805

	Alclofenac	400-1000mg	
	Diclofenac	25-75mg	25-50mg
	Fenbufen	200-900mg	300-600mg
5	Fenclofenac	200-600mg	
	Fenoprofen	200-800mg	300-600mg
	Flufenamic acid	50-250mg	
	Flurbiprofen	25-100mg	
10	Ibuprofen	50-800mg	200-600mg
	Indomethacin	20-100mg	25-75mg
	Indoprofen	50-200mg	100-200mg
15	Ketoprofen	50-200mg	
	Meclofenamic acid	50-200mg	
	Naproxen	250-1000mg	500-750mg
	Sulindac	100-200mg	
20	Tolmetin	200-800mg	200-600mg

25 In a particularly preferred embodiment of the present composition the narcotic analgesic phase contains codeine (as its phosphate salt) and the non-steroidal anti-inflammatory phase contains ibuprofen (as the free acid).

As mentioned above, when the present inventors attempted to prepare narcotic analgesic/non-steroidal anti-inflammatory carboxylic acid (especially codeine/ibuprofen) tablets as in EP 68838A they found that the tablets exhibited poor pharmaceutical qualities. This was surprisingly found to be caused primarily by incompatibility between the narcotic analgesic (codeine), the non-steroidal anti-inflammatory carboxylic acid (ibuprofen) and the lubricant employed, magnesium stearate.

Having made this observation, the present inventors then overcame these problems by an inventive combination of devices. These were

- (i) Separating the narcotic analgesic or salt thereof and the non-steroidal anti-inflammatory carboxylic acid or salt or ester thereof in a multi-phase, preferably layered, tablet,
- (ii) Removing stearic acid and/or stearate salts (especially magnesium stearate) from the composition, and

- (iii) Adding at least one self lubricating, direct compression aid, preferably a self lubricating, direct compression aid, to the mixtures used to form both the at least one narcotic analgesic and the at least one non-steroidal anti-inflammatory phases of the tablet in order to provide the lubrication necessary in tablet formation.

The self lubricating compression aids, preferably self lubricating, direct compression aids, employed in the present pharmaceutical composition combine at least two properties required of tablet vehicles. First they produce hard, stable tablets via compression, preferably via direct compression, and second they act as a lubricant to facilitate tablet ejection after compression. Examples of such compression aids will be well known to those skilled in the tablet formulation art. Amongst the aids that are preferred in the present composition are Elcema G-250 (Trade Mark, Degussa, cellulose granules derived from powdered cellulose N.F.), Starch 1500 (Trade Mark, Colorcon, a free flowing, directly compressible starch), and, which is particularly preferred, microcrystalline cellulose, especially Avicel (Trade Mark, FMC).

In addition to self lubricating, compression aids, the present composition may also contain, in one or more of its phases, other additives and components, provided they are compatible with the narcotic analgesic or salt thereof and the non-steroidal anti-inflammatory carboxylic acid or salt or ester thereof. Suitable materials include

- (a) Binders, such as cellulose and its derivatives, e.g. ethyl cellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, starches, polyvinyl pyrrolidone, natural gums and gelatin,
- (b) Glidants, such as talc and fumed silica,
- (c) Anti-Adherents, such as talc, fumed silica and corn starch,

		<u>mg/tablet</u>
5	Ibuprofen	200.0
	Codeine Phosphate	12.5
	Microcrystalline cellulose	
10	(Avicel PH102, Trade Mark)	65.4
	Sodium Starch Glycollate	
	(Explotab, Trade Mark)	45.0
	Hydroxypropyl methyl cellulose	
15	(viscosity, 3 cps)	7.1

20 When tablets prepared in this manner were compressed to crushing strengths of 9-17 kp, they exhibited sticking and ejection problems. The tablets, when prepared, had unacceptably long disintegration times.

25 C. Bi-Layer Formulation with Magnesium Stearate Present as a Lubricant

An ibuprofen layer having the following ingredients (in mg) was prepared by a wet granulation process,

30	Ibuprofen	200.00
	Microcrystalline cellulose	
	(Avicel PH102)	70.84
	Sodium Starch Glycollate	
35	(Explotab)	45.00
	Hydroxypropylmethyl cellulose	
	(3 cps)	8.16
40	Sodium Lauryl Sulphate	1.00
	Erythrosine Aluminium Lake	3.28

45 A codeine layer having the following ingredients (in mg) was prepared by a wet granulation process.

50	Codeine Phosphate	12.5
	Dicalcium Phosphate	289.5
	Hydroxypropylmethyl cellulose	
	(3 cps)	8.7
55	Sodium Starch Glycollate	12.6
	Magnesium Stearate	1.7

When the two layers were compressed together the codeine content decreased markedly after short term stability at room and elevated temperatures. Also a brown colour formed, especially at the interface between the two layers.

5

#### D. Bi-Layer Formulation with Magnesium Stearate as Lubricant

The ibuprofen layer was prepared as described in Example C. The codeine layer was prepared from the following ingredients (in mg) by a wet granulation process,

10

	Codeine Phosphate	12.5
	Microcrystalline cellulose	
15	(Avicel PH102)	267.0
	Hydroxypropyl methyl cellulose	
	(3 cps)	7.0
20	Sodium Starch Glycollate	
	(intragranular)	3.0
	Sodium Starch Glycollate	
	(extragranular)	9.0
25	Magnesium Stearate	1.5

30

When the codeine layer was compressed it was found that crushing strengths above 6 kp were difficult to achieve even with increasing compression forces.

#### Examples According to the Invention

35

##### Example 1

##### Ibuprofen layer

40

An ibuprofen layer having the following ingredients (in mg) was prepared by a wet granulation process.

45

	Ibuprofen	200.0
	Microcrystalline cellulose	
	(Avicel PH102)	65.0
50	Sodium Starch Glycollate	20.0
	Hydroxypropylmethyl cellulose	
	(3 cps)	15.0

55



(d) Disintegrants, such as starch and its derivatives, (e.g. sodium starch glycollate), microcrystalline cellulose, croscarmellose sodium (Ac-Di-Sol, Trade Mark), low substituted hydroxypropyl cellulose and cross-linked polyvinylpyrrolidone,

(e) Colorants, Flavorants and Sweeteners.

5 In addition to the above materials, in a further aspect of the present composition, there is at least one non-steroidal anti-inflammatory and/or narcotic analgesic phases may also contain substances suitable for the formation of a controlled release formulation. In particular the phase or phases may contain a hydrated water soluble hydroxy alkyl cellulose, especially hydroxyethyl cellulose, and a higher aliphatic alcohol, especially cetostearyl alcohol, as described in British Patent No. 1405088 (equivalent to US 3965256 and  
10 US 4235870), the contents of which documents are herein incorporated by way of reference.

Advantageously, the present multi-phase tablet may have, as one of its phases, a protective coating which may, for example, serve to mask the taste of both the non-steroidal anti-inflammatory carboxylic acid or salt or ester thereof and the narcotic analgesic or salt thereof. Suitable coating materials, which must be compatible with both the anti-inflammatory carboxylic acid or salt or ester thereof and the narcotic analgesic  
15 or salt thereof will be known to those skilled in this art. An example favoured by the present inventors uses hydroxypropyl methyl cellulose as the film former and propylene glycol as the plasticiser.

The precise amount of non-steroidal anti-inflammatory carboxylic acid or salt or ester thereof and narcotic analgesic or salt thereof present in the present pharmaceutical composition will be determined by, amongst other factors,

20 (a) the number of times per day the composition is to be administered,

(b) whether the at least one non-steroidal anti-inflammatory and/or narcotic analgesic phases are a normal or controlled release formulation, and

(c) the type of treatment required and stage of treatment reached by the patient.

For most of the therapeutic applications (e.g. treatment of pain and inflammation) envisaged by the  
25 present inventors, tablets of the present type will contain an amount of narcotic analgesic and non-steroidal anti-inflammatory carboxylic acid as set out in the Table above. If a salt or ester is employed the dose will be adjusted accordingly to give the required amount of base or acid. Thus, tablets containing ibuprofen and codeine will preferably contain between 50 and 800 mg, especially between 200 and 600 mg, of ibuprofen and between 5 and 60 mg, especially between 7.5 and 30 mg, of codeine.

30 The amount and/or ratio of self lubricating, compression aids, together with, as required, binders, glidants, anti-adherents, disintegrants, colorants, flavorants, sweeteners, etc. contained in the present pharmaceutical composition is determined by, amongst other factors,

(a) the amount of non-steroidal anti-inflammatory carboxylic acid or salt or ester thereof and narcotic analgesic or salt thereof present in the tablet's phases,

35 (b) the requirement of tablet integrity,

(c) the time for tablet disintegration required,

(d) the rate of tablet dissolution required,

(e) the requirement of tablet content uniformity, and

(f) the weight, thickness and size of the tablet.

40 Given the number of variables involved in the formulation of a pharmaceutical composition according to the present invention, it is difficult to give specific ranges for the concentrations of the above materials. In a preferred embodiment of the present pharmaceutical composition, however, especially wherein the at least one self lubricating compression aid comprises microcrystalline cellulose, the concentration of the compression aid in the at least one non-steroidal anti-inflammatory phase is between 10% and 90%, especially  
45 between 15% and 40%, by wt. (of the phase), whilst the concentration of the compression aid in the at least one narcotic analgesic phase is between 50% and 99%, especially between 70% and 95%, by wt. of the phase.

The present pharmaceutical composition may be prepared by direct compression, but is preferably prepared by wet granulation techniques. Thus, in a further aspect of the present invention, there is provided  
50 a wet granulation process for the preparation of a pharmaceutical composition according to this invention comprising

(a) granulating a narcotic analgesic or an analgesically effective salt thereof with at least one self lubricating, compression aid to form narcotic analgesic granules,

55 (b) granulating a non-steroidal anti-inflammatory carboxylic acid or an anti-inflammatory salt or ester thereof with at least one self lubricating, compression aid to form non-steroidal anti-inflammatory granules, and

(c) compressing the narcotic analgesic granules and the non-steroidal anti-inflammatory granules to form a multi-phase tablet.

In both steps (a) and (b) of the above process two methods of granulation may be used. In the first method, the drug, the compression aid and a binder are dry mixed. The mixed powders are then granulated by wetting with a solvent. In the second method, the drug and the compression aid are dry mixed and then granulated by wetting with a solution of a binder.

Suitable binders for these methods are hydroxypropylmethyl cellulose or polyvinylpyrrolidone.

The present pharmaceutical composition, together with processes for its preparation, will now be described by way of example only.

#### Comparative Examples

##### A. Combination of Ibuprofen and Codeine within a Single Layer Tablet with Magnesium Stearate as Lubricant

Single layer tablets were prepared from the following ingredients using a wet granulation process,

		<u>mg/tablet</u>
	Ibuprofen	200.00
	Codeine Phosphate	12.50
	Microcrystalline Cellulose	
	(Avicel PH 102)	23.75
	Croscarmellose Sodium	
	(Ac-Di-Sol)	5.00
	Hydroxypropylmethyl cellulose	
	(6 cps)	3.75
	Magnesium Stearate	2.45

These tablets had poor disintegration times, poor crushing strengths and exhibited sticking problems on compression.

##### B. Combination of Ibuprofen and Codeine within a Single Layer Tablet

Single layer tablets were prepared from the following ingredients using a wet granulation process,

The ibuprofen, microcrystalline cellulose, sodium starch glycolate and hydroxypropyl methyl cellulose were dry mixed. Water was then added to the dry powder and the mixture was granulated to give pharmaceutical ibuprofen containing granules.

5

#### Codeine layer

A codeine layer containing the following ingredients (in mg) was prepared by a wet granulation process.

10

	Codeine Phosphate	12.50
	Microcrystalline cellulose	
15	(Avicel PH102)	227.47
	Starch 1500 (Trade Mark),	
	Ingragranular	20.00
20	Starch 1500, Extragranular	40.00

Codeine Phosphate, microcrystalline cellulose and intragranular Starch 1500 were dry mixed. Water was then added and the mixture was granulated to form pharmaceutical, codeine containing granules. Starch 1500 was then mixed with the granules. Finally the codeine and ibuprofen granules were compressed to give an ibuprofen-codeine bilayer tablet with a crushing strength of 11-12 kp.

30

#### Example 2

The procedure of Example 1 was followed except that the ibuprofen layer had the following composition (in mg),

35

	Ibuprofen	200.00
	Microcrystalline cellulose	
40	(Avicel PH102)	50.00
	Sodium Starch Glycolate	12.50
	Hydroxypropylmethyl cellulose	
45	(3 cps)	12.50

#### Example 3

The procedure of Example 1 was followed except that the ibuprofen layer had the following composition (in mg),

50

55

	Ibuprofen	200.00
	Microcrystalline cellulose	
	(Avicel PH102)	70.84
5	Sodium Starch Glycollate	45.00
	Hydroxypropylmethyl cellulose	
	(3 cps)	8.16
10	Sodium Lauryl Sulphate	1.00
	Erythrosine Aluminium Lake	3.28

15 The sodium lauryl sulphate and the erythrosine aluminium lake were mixed in the dry powder prior to the addition of water. In this case the resulting tablet was coated using hydroxypropylmethyl cellulose as film former, and PEG400 as plasticiser.

#### 20 Example 4

##### Ibuprofen layer

This was prepared as described in Example 3.

##### 25 Codeine layer

A codeine layer containing the following ingredients (in mg) was prepared by a wet granulation process.

30	Codeine Phosphate	12.50
	Microcrystalline cellulose	
	(Avicel PH102)	227.50
35	Starch 1500	40.00
	Polyvinylpyrrolidone	
	(Kollidon K30, Trade Mark)	10.00
40	Microcrystalline cellulose	
	(Avicel PH101)	40.00

45 Codeine Phosphate, microcrystalline cellulose (Avicel PH102) and Starch 1500 were dry mixed. An aqueous solution of polyvinylpyrrolidone was then added to the dry powder and the mixture was granulated to give codeine granules. Microcrystalline cellulose (Avicel PH101) was then mixed with the granules. Finally the codeine and ibuprofen granules were compressed to give an ibuprofen-codeine bilayer tablet with a crushing strength of 11-12 kp.

#### 50 Example 5

55 The procedure of Example 4 was followed except that the ibuprofen layer had the following composition (in mg).

	Ibuprofen	200.00
	Microcrystalline cellulose	
5	(Avicel PH102)	68.59
	Sodium Starch Glycollate	45.00
	Hydroxypropylmethyl cellulose	
10	(3 cps)	8.16
	Erythrosine Aluminium Lake	3.25

#### 15 Example 6

The procedure of Example 5 was followed except that the amount of Starch 1500 in the codeine layer was reduced to 25.0 mg. In this case the resulting bilayer tablet was coated with hydroxypropylmethyl cellulose as film former, and propylene glycol as plasticiser.

20 Tablets prepared in accordance with Examples 1 to 6 above exhibited pharmaceutically acceptable properties with regard to stability, disintegration times and dissolution rates.

#### Example 7

##### 25 Ibuprofen Layer

Ibuprofen (30gm), microcrystalline cellulose (Avicel pH 102, 5.01gm), lactose anhydrous (5.01gm), hydroxyethyl cellulose (0.5gm), hydroxypropylmethyl cellulose (5cps, 0.95gm) and trisodium 7-hydroxy-8-(4-sulphonato-1-naphthylazo) naphthalene-1,3-di sulphonate (onceau 4R, Trade Mark, 0.43gm) were dry blended. To the mixture was added sufficient water to produce a granulated mass.

The wet granules were then partially dried in a Fluid Bed dryer at 50°C. The partially dried mass was granulated through a 12 mesh screen and then further dried. The dried granules were passed through a 16 mesh screen.

35 Molten cetostearyl alcohol (1.0gm) was then added, with mixing, to the granules. Finally, talc (0.4gm) was blended with the granules.

##### Codeine Layer

40 Codeine granules were prepared as described in Example 4 above.

Finally the codeine and the ibuprofen granules were compressed to give an ibuprofen-codeine bilayer tablet containing 300mg ibuprofen/12.5mg codeine phosphate and having a controlled release ibuprofen layer and a normal release codeine layer.

45 Tablets prepared in accordance with Example 7 exhibited pharmaceutically acceptable properties with regard to stability, disintegration times and dissolution rates.

#### Example 8

50 The procedure of Example 7 was followed except that the codeine layer had the following composition - (in mg).

55

	Codeine Phosphate	20.0
	Microcrystalline cellulose (Avicel PH 102)	364.0
	Starch 1500	40.0
5	Polyvinylpyrrolidone	16.0
	Microcrystalline cellulose	64.0

Again, tablets prepared in accordance with Example 8 exhibited pharmaceutically acceptable properties with regard to stability, disintegration times and dissolution rates.

#### Example 9

The procedure of Example 8 was followed. The tablets were then film coated with hydroxypropylmethyl cellulose as film former and propylene glycol as plasticiser.

#### Example 10

The procedure of Example 4 was followed except that the codeine layer had the following composition - (in mg),

	Codeine Phosphate	12.5
25	Microcrystalline cellulose (Avicel PH 102)	227.5
	Starch 1500	60.0

The tablets were film coated with hydroxypropylmethyl cellulose as film former and polyethylene glycol as plasticiser.

#### Example 11

The procedure of Example 4 was followed except that dihydrocodeine tartrate replaced codeine phosphate and the dihydrocodeine layer had the following composition (in mg),

40	Dihydrocodeine tartrate	30.0
	Microcrystalline cellulose (Avicel PH 102)	200.0
	Starch 1500	40.0
45	Polyvinylpyrrolidone (PVP-K30)	10.0
	Microcrystalline cellulose (Avicel PH 101)	30.0

#### Example 12

The procedure of Example 4 was followed except that naproxen replaced ibuprofen and the naproxen layer had the following composition (in mg),

	Naproxen	500.0
	Microcrystalline cellulose (Avicel PH 102)	150.0
5	Starch 1500	45.0
	Sodium Starch Glycollate (Explotab)	100.0
	Hydroxypropylmethyl cellulose	20.0

#### 10 Example 13

The procedure of Example 4 was followed except that flurbiprofen replaced ibuprofen and the flurbiprofen layer had the following composition (in mg),

15	Flurbiprofen	100.0
	Microcrystalline cellulose (Avicel PH 102)	35.0
20	Sodium Starch Glycollate	20.0
	Hydroxypropylmethyl cellulose	5.0
25	Erythrosine Aluminium Lake	1.5

#### 30 Claims

1. A pharmaceutical composition in the form of a multiphase tablet comprising at least one narcotic analgesic phase containing a therapeutically effective quantity of a narcotic analgesic or an analgesically effective salt thereof and at least one non-steroidal anti-inflammatory phase containing a therapeutically effective quantity of a non-steroidal anti-inflammatory carboxylic acid or an anti-inflammatory salt or ester thereof wherein the at least one narcotic analgesic phase is free from a non-steroidal anti-inflammatory carboxylic acid or salt or ester thereof, stearic acid and a stearate salt, and the at least one non-steroidal anti-inflammatory phase is free from a narcotic analgesic or salt thereof, stearic acid and a stearate salt, and further wherein both the at least one narcotic analgesic phase and the at least one non-steroidal anti-inflammatory phase contain at least one self-lubricating, compression aid, preferably at least one self lubricating, direct compression aid.
2. A composition according to claim 1 characterised in that the narcotic analgesic comprises a morphinan-6-ol or a morphinan-6-one derivative, preferably morphine, ethylmorphine, hydromorphone, hydrocodone, dihydrocodeine or codeine.
3. A composition according to claim 1 characterised in that the analgesically effective salt of the narcotic analgesic comprises codeine phosphate.
4. A composition according to any one of claims 1 to 3 characterised in that the non-steroidal anti-inflammatory carboxylic acid comprises a benzeneacetic acid, preferably alclofenac, diclofenac or fenclufenac, a 2-naphthylpropionic acid, preferably naproxen, or a 2-phenylpropionic acid, preferably fenoprofen, flurbiprofen, indoprofen, ketoprofen or ibuprofen.
5. A composition according to claim 4 characterised in that the non-steroidal anti-inflammatory carboxylic acid comprises ibuprofen.
6. A composition according to any one of claims 1 to 5 characterised in that the at least one self lubricating, compression aid is selected from microcrystalline cellulose and a free flowing, directly compressible starch.
7. A composition according to any one of claims 1 to 6 characterised in that the concentration of the compression aid in the at least one non-steroidal anti-inflammatory phase is between 10% and 90%, preferably between 15% and 40%, by wt.

8. A composition according to any one of claims 1 to 7 characterised in that the concentration of the compression aid in the at least one narcotic analgesic phase is between 50% and 99%, preferably between 70% and 95%, by wt.

9. A composition according to any one of claims 1 to 8 in the form of a layered, preferably bilayered, tablet.

10. A wet granulation process for the preparation of a pharmaceutical composition according to claim 1 comprising

(a) granulating a narcotic analgesic or an analgesically effective salt thereof with at least one self lubricating, compression aid to form narcotic analgesic granules,

(b) granulating a non-steroidal anti-inflammatory carboxylic acid or an anti-inflammatory salt or ester thereof with at least one self lubricating, compression aid to form non-steroidal anti-inflammatory granules, and

(c) compressing the narcotic analgesic granules and the non-steroidal anti-inflammatory granules to form a multiphase tablet.

Claims for the following Contracting State: AT

1. A process for the preparation of a pharmaceutical composition comprising forming a multiphase tablet in which at least one narcotic analgesic phase contains a therapeutically effective quantity of a narcotic analgesic or an analgesically effective salt thereof and at least one non-steroidal anti-inflammatory phase contains a therapeutically effective quantity of a non-steroidal anti-inflammatory carboxylic acid or an anti-inflammatory salt or ester thereof wherein the at least one narcotic analgesic phase is free from a non-steroidal anti-inflammatory carboxylic acid, or salt or ester thereof, stearic acid and a stearate salt, and the at least one non-steroidal anti-inflammatory phase is free from a narcotic analgesic, or salt thereof, stearic acid and a stearate salt, and further wherein both the at least one narcotic analgesic phase and the at least one non-steroidal anti-inflammatory phase contain at least one self-lubricating, compression aid, preferably at least one self-lubricating, direct compression aid.

2. A process according to claim 1 characterised in that the narcotic analgesic comprises a morphinan-6-ol or a morphinan-6-one derivative, preferably morphine, ethylmorphine, hydromorphone, hydrocodone, dihydrocodeine or codeine.

3. A process according to claim 1 characterised in that the analgesically effective salt of the narcotic analgesic comprises codeine phosphate.

4. A process according to any one of claims 1 to 3 characterised in that the non-steroidal anti-inflammatory carboxylic acid comprises a benzeneacetic acid, preferably alclofenac, diclofenac or fenclufenac, a 2-naphthylpropionic acid, preferably naproxen, or a 2-phenylpropionic acid, preferably fenoprofen, flurbiprofen, indoprofen, ketoprofen or ibuprofen.

5. A process according to claim 4 characterised in that the non-steroidal anti-inflammatory carboxylic acid comprises ibuprofen.

6. A process according to any one of claims 1 to 5 characterised in that the at least one self lubricating, compression aid is selected from microcrystalline cellulose and a free flowing, directly compressible starch.

7. A process according to any one of claims 1 to 6 characterised in that the concentration of the compression aid in the at least one non-steroidal anti-inflammatory phase is between 10% and 90%, preferably between 15% and 40%, by wt.

8. A process according to any one of claims 1 to 7 characterised in that the concentration of the compression aid in the at least one narcotic analgesic phase is between 50% and 99%, preferably between 70% and 95%, by wt.

9. A process according to any one of claims 1 to 8 in the form of a layered, preferably bilayered, tablet.

10. A wet granulation process for the preparation of a pharmaceutical composition according to claim 1 comprising

(a) granulating a narcotic analgesic or an analgesically effective salt thereof with at least one self lubricating, compression aid to form narcotic analgesic granules,

(b) granulating a non-steroidal anti-inflammatory carboxylic acid or an anti-inflammatory salt or ester thereof with at least one self lubricating, compression aid to form non-steroidal anti-inflammatory granules, and

(c) compressing the narcotic analgesic granules and the non-steroidal anti-inflammatory granules to form a multiphase tablet.





Europäisches Patentamt  
European Patent Office  
Office européen des brevets

(11) Publication number:

**0 220 805  
A3**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: 86306216.2

(51) Int. Cl.<sup>4</sup>: A61K 9/24

(22) Date of filing: 12.08.86

(30) Priority: 28.08.85 GB 8521350

(43) Date of publication of application:  
06.05.87 Bulletin 87/19

(84) Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE

(86) Date of deferred publication of the search report:  
29.07.87 Bulletin 87/31

(71) Applicant: Euroceltique SA  
122 Boulevard De La Petrusse  
Luxembourg(LU)

(72) Inventor: Elger, Gordon Anthony  
99 Greenfields Earith  
Huntingdon Cambs.(GB)  
Inventor: Leslie, Stewart Thomas  
4 Babraham Road  
Cambridge, CB2 2RA(GB)  
Inventor: Malkowska, Sandra Therese  
Anolnette  
14 Abrahams Close  
Landbeach Cambridge(GB)  
Inventor: Miller, Ronald Brown  
Bruderholzallee, 191  
Basel 4059(CH)  
Inventor: Neale, Phillip John  
28, London Road  
Harston Cambridge, CB2 5QH(GB)

(74) Representative: James, Stephen Richard,  
Napp Pharmaceutical Group Cambridge  
Science Park Milton Road  
Cambridge CB4 4GW(GB)

(54) Multiphase tablet and process for the preparation thereof.

EP 0 220 805 A3  
(57) A pharmaceutical composition in the form of a multiphase (especially a bilayered, optionally coated) tablet. The tablet has a narcotic analgesic phase containing a therapeutically effective quantity of a narcotic analgesic or an analgesically effective salt thereof (e.g. codeine phosphate) and a non-steroidal anti-inflammatory phase containing a therapeutically effective quantity of a non-steroidal anti-inflammatory carboxylic acid or an anti-inflammatory salt or ester thereof (e.g. ibuprofen). The narcotic analgesic phase is free from a non-steroidal anti-inflammatory carboxylic acid or salt or ester thereof, stearic acid and a stearate salt, and the non-steroidal anti-inflammatory phase is free from a narcotic analgesic or salt thereof, stearic acid and a stearate salt. Further,

both the narcotic analgesic phase and the non-steroidal anti-inflammatory phase contain a self-lubricating, compression aid, especially a self-lubricating, direct compression aid, such as micro-crystalline cellulose.



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application number

EP 86 30 6216

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
P,X	EP-A-0 159 852 (MALLINCKRODT, INC.) * Page 2, lines 23-30; page 3, line 31 - page 5, line 6; page 9, example 7; page 10, lines 4-14; claims 1-2,5-10 *	1-5,7, 8,10	A 61 K 9/24
Y	--- GB-A- 818 251 (THE BRITISH DRUG HOUSES LTD) * Whole document *	1-10	
Y	--- EP-A-0 024 690 (E.I. DU PONT DE NEMOURS & CO.) * Pages 6,7; examples 1,2; claims *	1-10	
Y	--- FR-A-2 081 330 (WILD) * Page 8, example 2 *	1-10	TECHNICAL FIELDS SEARCHED (Int. Cl.4)
Y,D	--- EP-A-0 068 838 (THE UPJOHN CO.) * Pages 5,6, example 3; pages 7,8, example 8; page 9, example 12; claims *	1-10	A 61 K
P,Y	--- US-A-4 569 937 (BAKER et al.) * Columns 6,7, examples 13-15 *	1-10	
--- -/-			
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 22-04-1987	Examiner BENZ K.F.
<b>CATEGORY OF CITED DOCUMENTS</b>			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO Form 1503 03 82



DOCUMENTS CONSIDERED TO BE RELEVANT				Page 2												
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)													
A	Hagers Handbuch der Pharmazeutischen Praxis, vol. 7, part A, 1971, page 689, Editor: P.H. LIST et al., Springer Verlag, Berlin, DE * Page 689: "Mehrschichttabletten" * -----	9														
			TECHNICAL FIELDS SEARCHED (Int. Cl.4)													
The present search report has been drawn up for all claims																
Place of search THE HAGUE		Date of completion of the search 22-04-1987	Examiner BENZ K.F.													
<table border="0"><tr><td><b>CATEGORY OF CITED DOCUMENTS</b></td><td><b>T : theory or principle underlying the invention</b></td></tr><tr><td>X : particularly relevant if taken alone</td><td><b>E : earlier patent document, but published on, or after the filing date</b></td></tr><tr><td>Y : particularly relevant if combined with another document of the same category</td><td><b>D : document cited in the application</b></td></tr><tr><td>A : technological background</td><td><b>L : document cited for other reasons</b></td></tr><tr><td>O : non-written disclosure</td><td><b>&amp; : member of the same patent family, corresponding document</b></td></tr><tr><td>P : intermediate document</td><td></td></tr></table>					<b>CATEGORY OF CITED DOCUMENTS</b>	<b>T : theory or principle underlying the invention</b>	X : particularly relevant if taken alone	<b>E : earlier patent document, but published on, or after the filing date</b>	Y : particularly relevant if combined with another document of the same category	<b>D : document cited in the application</b>	A : technological background	<b>L : document cited for other reasons</b>	O : non-written disclosure	<b>&amp; : member of the same patent family, corresponding document</b>	P : intermediate document	
<b>CATEGORY OF CITED DOCUMENTS</b>	<b>T : theory or principle underlying the invention</b>															
X : particularly relevant if taken alone	<b>E : earlier patent document, but published on, or after the filing date</b>															
Y : particularly relevant if combined with another document of the same category	<b>D : document cited in the application</b>															
A : technological background	<b>L : document cited for other reasons</b>															
O : non-written disclosure	<b>&amp; : member of the same patent family, corresponding document</b>															
P : intermediate document																

EPO Form 1503 (03/82)

